Abstract: Human papillomavirus (HPV) is one of the common sexually transmitted diseases. High-risk human papillomavirus (hrHPV) persistent infection is a major risk factor for cervical precancerous lesions and cervical cancer. HPV types 16 and 18 cause about 70% of cervical cancer worldwide. Cervical cancer screening can reduce the risk of cervical cancer, but it can not prevent HPV infection. Many reports indicate that an effective HPV vaccine can reduce HPV-associated cervical cancer, genital tract spasm morbidity and mortality. Therefore, in order to prevent such diseases effectively, the research on HPV preventive vaccines has been carried out worldwide. At present, the HPV vaccines for clinical application include HPV 2-valent vaccine, 4-valent vaccine and 9-valent vaccine, which can effectively prevent the infection of the corresponding HPV type, and greatly reduce the incidence and mortality of cervical lesions and cervical cancer. This article reviews HPV, cervical cancer, the immunogenicity and number of inoculation doses and clinical application of these three types of HPV vaccines..

Key words: Papillomaviridae, Uterine cervical neoplasms, Papillomavirus vaccines